Morgan Stanley
FDMT icon

Morgan Stanley’s 4D Molecular Therapeutics FDMT Stock Holding History

Morgan Stanley’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.22M Sell
345,410
-327,285
-49% -$2.85M ﹤0.01% 4429
2025
Q4 		$5.05M Sell
672,695
-163,216
-20% -$1.66M ﹤0.01% 4162
2025
Q3 		$7.26M Sell
835,911
-88,765
-10% -$531K ﹤0.01% 3835
2025
Q2 		$3.43M Sell
924,676
-852,067
-48% -$3M ﹤0.01% 4355
2025
Q1 		$5.74M Sell
1,776,743
-86,314
-5% -$407K ﹤0.01% 3810
2024
Q4 		$10.4M Buy
1,863,057
+160,718
+9% +$1.26M ﹤0.01% 3376
2024
Q3 		$18.4M Buy
1,702,339
+242,105
+17% +$4.02M ﹤0.01% 2885
2024
Q2 		$30.7M Sell
1,460,234
-89,492
-6% -$2.24M ﹤0.01% 2212
2024
Q1 		$49.4M Sell
1,549,726
-1,587,842
-51% -$40.5M ﹤0.01% 1772
2023
Q4 		$63.6M Buy
3,137,568
+1,671,700
+114% +$22M ﹤0.01% 2203
2023
Q3 		$18.7M Sell
1,465,868
-101,891
-6% -$1.7M ﹤0.01% 2528
2023
Q2 		$28.3M Sell
1,567,759
-174,118
-10% -$3.21M ﹤0.01% 2117
2023
Q1 		$29.9M Buy
1,741,877
+283,305
+19% +$5.51M ﹤0.01% 2012
2022
Q4 		$32.4M Sell
1,458,572
-563,001
-28% -$8.7M ﹤0.01% 1891
2022
Q3 		$16.3M Buy
2,021,573
+1,708,534
+546% +$15.5M ﹤0.01% 2417
2022
Q2 		$2.19M Sell
313,039
-106,997
-25% -$1.04M ﹤0.01% 4460
2022
Q1 		$6.35M Sell
420,036
-14,042
-3% -$221K ﹤0.01% 3421
2021
Q4 		$9.52M Buy
434,078
+65,627
+18% +$1.61M ﹤0.01% 3001
2021
Q3 		$9.94M Sell
368,451
-62,336
-14% -$1.78M ﹤0.01% 2894
2021
Q2 		$10.4M Buy
430,787
+158,641
+58% +$4.86M ﹤0.01% 2932
2021
Q1 		$11.8M Buy
272,146
+26,441
+11% +$1.17M ﹤0.01% 2487
2020
Q4 		$10.2M Buy
+245,705
New +$10.1M ﹤0.01% 2489

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Morgan Stanley's FDMT Position: Q1 2026 in Review

Morgan Stanley reduced its 4D Molecular Therapeutics (FDMT) stake by 49% in Q1 2026, selling an estimated $2.85M and leaving 345,410 shares worth $3.22M. The position accounts for ﹤0.01% of the portfolio, ranked #4429.

Morgan Stanley first reported a position in FDMT in Q4 2020 and has held it in 22 quarters since. The position peaked at $63.6M in Q4 2023. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Morgan Stanley held 345,410 shares of 4D Molecular Therapeutics worth $3.22M as of Q1 2026.
  • Morgan Stanley sold 327,285 4D Molecular Therapeutics shares in Q1 2026, an estimated $2.85M.
  • 4D Molecular Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #4429 holding.
  • Morgan Stanley first reported a position in 4D Molecular Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Morgan Stanley's 4D Molecular Therapeutics position peaked at $63.6M in Q4 2023.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.